The inhibitory effect of norharman on morphine withdrawal syndrome in rats: comparison with ibogaine.
S L Cappendijk, D Fekkes, M R Dzoljic
Behavioural Brain Research November 16, 1994 DOI: 10.1016/0166-4328(94)90080-9 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Morphine-dependent rats |
| Interventions | Norharman Ibogaine |
| Dose | 20 mg/kg norharman, 40 mg/kg ibogaine, 4 mg/kg naloxone |
| Topics | Ibogaine |
| Citations | 57 |
| Key findings | Norharman and ibogaine each attenuated naloxone-precipitated withdrawal syndrome in morphine-dependent rats. |
Abstract
Norharman (20 mg/kg, i.p.) and ibogaine (40 mg/kg, i.p.) significantly attenuated naloxone (4 mg/kg, i.p.)-precipitated withdrawal syndrome in morphine-dependent rats. Several withdrawal signs, such as teeth-chattering, chewing, penile licking and diarrhoea, were decreased by both norharman and ibogaine. In addition, norharman reduced also the withdrawal grooming and rearing. It is concluded that both norharman and ibogaine are inhibitors of withdrawal syndrome in morphine-dependent rats.